www.StockMarketingInc.com: Sign Up & Be in the Know!! Our Alerts are Making our Members $$!! SRGL,IMUC,CGLD,ATNP,PWRM,ENCR

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: SRGL - Source Gold Corp.)

LATEST NEWS!!

Source Gold Corp Identifies High Grade Gold and Copper From Initial Sampling Program

Dec 02, 2009 -- Source Gold Corp. (OTCBB: SRGL | Quote | Chart | News | PowerRating) is pleased to announce that the company has received initial results from samples assayed by Accurassay Laboratories in Thunder Bay, Ontario, Canada. The samples were taken from the KRK West Property in the Beardmore-Geraldton Greenstone Belt in Northwestern Ontario, Canada.

Based upon the initial exploration program of trenching, channel sampling, geological mapping and a TEM survey covering our claim group on over 15 square miles of the KRK West Property, the Company has identified three main areas of interest.

The first area of interest is the Little Brother Claim Group, where a number of samples were taken from an area along a northern grandiorite with intermediate volcanics, which yielded visible gold occurrences. Assay results from this initial sampling program have yielded very encouraging high-grade gold assays of 9.55/oz per ton (270.74 grams/ton). Separate samples assayed from this area have similarly yielded very high-grade copper of 15.5%.

The second area of interest is close to the eastern portion of the property east of Peddle Lake. This area is the most active on the property where a number of drill collars belonging to a previous operator were drilled during the 1970's. The ground observations in the trenches and historical assessment have indicated a large disrupted zone carrying high gold and silver values.

The third area of interest is the most westerly area of the property near Musca Lake, along a continuous shear zone. The Musca Lake zone consists of a quartz flooded shear which pinches and swells along its strike length.

"These high-grade gold and copper assay results are amongst the highest values I have witnessed to date in my career," Lauren Notar, President of Source Gold Corp. comments. "We are very excited by our initial trenching and sampling program which has uncovered a number of highly mineralized areas of interest. As more samples are assayed, we look forward to better understanding the distribution of the occurrences and controls on mineralization within our claim group." The Company will continue with an aggressive exploration program, centered on the major fault lines and areas of interest which traverse our mineral claims. Accurassay Laboratories is currently processing more than 250 trench samples from the Company's three main areas of interest on the KRK West Property, and further assay results are expected within the next few weeks.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: IMUC - ImmunoCellular Therapeutics, Ltd.)

LATEST NEWS!!

ImmunoCellular Therapeutics Enters into Option Agreement with The University of Texas M. D. Anderson Cancer Center for a Novel Cancer Stem Cell Therapy

LOS ANGELES, Dec 02, 2009 -- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC | Quote | Chart | News | PowerRating) (IMUC), a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center relating to an immunotherapy targeting cancer stem cells (CSCs) which has demonstrated in pre-clinical animal models significant abilities to target and destroy CSCs. This latest agreement bolsters the Company's portfolio of technologies targeting CSCs. This portfolio already features several promising therapies, including ICT-107, a dendritic cell based immunotherapy that recently completed a phase I study, and ICT-121, an off-the-shelf peptide targeting CSCs.

The technology being optioned from M. D. Anderson is an immunotherapy targeting cancer stem cells using abnormal Notch and Numb pathways, two mechanisms implicated in many common solid tumors including breast, colon and ovarian cancers. Research indicates that cytotoxic T cells induced by these peptides preferentially target cancer stem cells derived from breast cancer, ovarian cancer and pancreatic cancer; expression of these peptides has been demonstrated on clinical samples from ovarian cancer patients. The therapy was developed at M. D. Anderson by Dr. Constantin G. Ioannides and Satoko Matsueda. Dr. Ioannides is also credited, along with others, with the development of the E75 peptide targeting Her-2/neu, which has been tested in a phase II study to prevent breast cancer recurrence.

"This latest addition to our portfolio of CSC targeting therapies should serve to further increase our ability to specifically identify and destroy these important tumor building blocks by targeting additional pathways that were not addressed by our current portfolio," remarked Manish Singh, Ph.D., president and chief executive officer of IMUC. "By acquiring rights to this previously unaddressed pathway, we are now well positioned to continue development of a therapy that will enhance our ability to target these important cells, which we believe may lead to more effective and better tolerated treatments that are capable of targeting a number of different tumor types." About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The company's "off the shelf" therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the first quarter of 2010. IMUC also recently completed a Phase I trial of its dendritic cell-based clinical product candidate for glioblastoma. IMUC has entered into a research and license option deal with the Roche Group for one of its monoclonal antibodies for the diagnosis and treatment of ovarian cancer and multiple myeloma, that provides for potential licensing and milestone payments of $32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit www.imuc.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: CGLD - Capital Gold Corp.)

LATEST NEWS!!

Capital Gold Corporation Announces Initial Drilling Results For Its Saric Properties

NEW YORK, Dec 02, 2009 -- Capital Gold Corporation (TSX: CGC; OTC Bulletin Board: CGLD | Quote | Chart | News | PowerRating) today announced drilling results of its early stage exploration campaign including excerpts from its recent drilling work on its Saric properties located in Northern Sonora, Mexico.

"We are pleased with the initial exploration efforts at our Saric properties having intersected gold and silver mineralization from many of the recent drill holes targeted at identifying a potential bulk tonnage gold mineralized zone," John Brownlie, President and Chief Operating Officer of Capital Gold said.

Initial exploration work conducted from April 2008 to the present consisted of geological mapping, systematic geochemical rock and soil sampling, geophysical surveys and open trench sampling, the results of which were positive in identifying mineralized anomalies. In addition to this preliminary surface exploration work, 73 reverse circulation drill holes totaling 6,121 meters have been drilled by Layne de Mexico of Hermosillo on the property, and more recently a one meter interval topographic survey was also undertaken over the concession area.

"The Sombreretillo-Cometa and Gila Monster zones have initially been identified as those areas most likely to contain bulk tonnage mineralization suitable for open pit mining. Virtually all of the drill holes in these areas have intercepted gold and silver mineralization at near surface," Brownlie added.

Property Details The properties are located west of the village of Saric in Northern Sonora, Mexico and are accessible by paved road 60 miles North East of Capital Gold's El Chanate mine located near the towns of Caborca and Altar. Capital Gold acquired the El Oso project concession group from local prospectors in early 2008. The claim group consists of leased and owned concessions totaling 4,093 hectares. The topography consists of low rolling hills with an average elevation of 1,050 meters. The location of the property allows Capital Gold to utilize its infrastructure at "El Chanate" during the exploration period and would take advantage of this if a mineable resource was identified at the Saric concessions.

Geological Setting The area of interest is underlain by Cretaceous and Tertiary age volcanic and intrusive rocks. These volcanic rocks rest on or intrude older granodiorite. Mineralization is structurally controlled and associated with low angle zones which trend northeast. Mineralization is low sulfidation and is associated with iron oxide alteration, and quartz pyrite stockwork veining. During the next phase of drilling, a series of core holes is planned to better understand the lithology and mineralization within the mineralized structure.

Metallurgical Testing Preliminary testing at Capital Gold's metallurgical laboratory at "El Chanate" on surface samples has demonstrated good cyanide solubility and low reagent consumption. In addition, test work on drill hole mineralized material show good gold and silver cyanide solubility.

Quality Control & Quality Assurance Since the inception of the exploration at the Saric properties, SRK Consulting of Lakewood, Colorado has been involved during each step of the process and has reviewed and commented on the results of the work completed to date and will assist Capital Gold on the next phase of the exploration program.

About Capital Gold Capital Gold Corporation (CGLD: CGC) is a gold production and exploration company. Through its Mexican subsidiaries and affiliates, it owns 100% of the "El Chanate" gold mine located near the town of Caborca in Sonora, Mexico. It also owns and leases mineral concessions near the town of Saric, also in Sonora, that are undergoing preliminary exploration for gold and silver mineralization. Additional information about Capital Gold and the El Chanate Gold Mine is available on the Company's website, www.capitalgoldcorp.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(PINKSHEETS: ATNP - Atlantis Technology Group)

LATEST NEWS!!

Atlantis Technology Group Subsidiary Global Online Television Executed a Contract With FreeCause, Inc. to Provide a Shopping Mall and Search Toolbar for the GOTV IPTV Service

MIAMI, FL, Dec 02, 2009 -- Atlantis Technology Group (PINKSHEETS: ATNP | Quote | Chart | News | PowerRating) subsidiary Global Online Television Corporation (GOTV) (www.gotvco.com) executed a contract with FreeCause, Inc. (www.freecause.com) to provide a shopping mall and search toolbar for the GOTV IPTV Service. The shopping mall will be set to a specific channel enabling viewers to shop directly from their TV at numerous stores like Best Buy, Expedia, Wal-Mart, Amazon.com, Target, Office Max, Petco, Macys, and many more. A complete list of over 2,000 online shopping stores will be available on the company website.

A separate channel will be designated for individual store sales enabling customers to scroll through the various sales without actually visiting the individual store's home page.

Each time an individual makes a purchase from the shopping mall channel GOTV will receive revenue from the sale. It is estimated from previous marketing experience and other clients that each individual subscriber generates approximately $34.00 per month in gross sales revenue.

The toolbar will be installed directly into the web browser utilizing each individual search as a possible revenue stream. Additional target marketing will be gathered from each customers search criteria and purchases. This will enable the shopping mall to show sales on what types of products and stores each customer has an interest in.

Global Online Television Corporation projects the gross sales revenue in 2010 to be over $40 million for the shopping mall channel and toolbar yielding net revenues of over $2 Million.

About FreeCause, Inc.

FreeCause, Inc. As a global industry leader, FreeCause is dedicated to provide cutting-edge engagement solutions that help to unlock the value of constituent relationships for the benefit of nonprofit organization and other affinity based groups.

About Global Online Television (GOTV) Global Online Television Corporation was originally established by Atlantis Technology Group as a media subsection that would develop research in the advancement of media-based technology. GOTV brings the largest internet protocol television networks together for your home television viewing. IPTV is TV to TV, using standard broadband connections. By using the IPTV and Microsoft Windows Media Player, the video stream is delivered to your home television over broadband internet connection. Any broadband internet connection can be used, so there is no need to change providers. It is fast, simple, and affordable. To find out more about Global Online Television please visit http://www.gotvco.com.

About Atlantis Technology Group Atlantis Technology Group was formed to establish privately held and publicly traded technology companies that focus primarily on high-growth investments that are at the leading edge of business and technological innovation.

To find out more about Atlantis Technology Group please visit http://www.atlantistechnologygroup.com

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: PWRM - Power3 Medical Products, Inc.)

LATEST NEWS!! Power3's Goldknopf Presents at International Molecular Diagnostic Meeting in Beijing

President, Chief Scientific Officer Keynotes and Chairs Session on November 20, 2009, Meets With Leading Biotech Company, Explores Development and Launch of Diagnostic Tests in Chinese Market

HOUSTON, Dec 1, 2009 -- Power3 Medical Products, Inc. (OTCBB:PWRM), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests reports that the company's President and CSO, Dr. Ira Goldknopf, delivered an invited Keynote address and chaired a session on "Biomarkers and Diagnostics in Personalized Medicine (Track 6-4)," at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting was "New Leadership of Personalized Medicine." Dr. Goldknopf described the company's unique ability to employ Power3's blood protein biomarkers to differentially diagnose mild Alzheimer's and Parkinson's diseases, distinguish between them, distinguish from normal controls, distinguish from patients with Alzheimer's and Parkinson's like disorders (disease controls) and distinguish drug naive and drug treated patients. He also presented results for early diagnosis of invasive breast cancer with and without ductal carcinoma in situ, distinguishing between them, distinguishing them from normal and benign controls. The final topic covered was the discovery of biomarkers in bone marrow cells from chronic myelogenous leukemia patients that predict whether they would respond to the drug imatinib mesylate (Gleevec).

"Power3 has begun confidential discussions with a flagship Chinese Biotechnology Company with an eye to co-develop high throughput blood tests for the Chinese market," said Dr. Goldknopf. "We intend to establish a major worldwide presence." "We are extremely proud and excited about the interest generated by Dr. Goldknopf's presentation of our results at this international meeting," said Ms. Helen Park, Power3's CEO, "particularly the new findings in clinical validation of the company's biomarkers and unique blood tests and the continuing discussions leading to their commercialization in China." About Power3 Medical Products, Inc.: Power3 Medical Products (OTCBB:PWRM) (www.Power3Medical.com) is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro(R)) and breast cancer (BC-SeraPro(TM)). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer's disease (NuroPro-AD), Parkinson's disease (NuroPro-PD) and breast cancer in 2010, followed by filings with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer's, and Parkinson's diseases, and breast cancer.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(PINKSHEETS: ENCR - Encounter.com, Inc.)

LATEST NEWS!!

Encounter.com, Inc. Acquires RTR Media, Inc., a Premier Video Technology Platform

NEW YORK, NY, Dec 02, 2009 -- Encounter.com, Inc. (PINKSHEETS: ENCR | Quote | Chart | News | PowerRating) announced that it has completed the acquisition of RTR Media, Inc., a leading video technology platform provider.

Encounter.com, Inc.'s President, Richard DiBiase, stated, "Having a vested interest in such companies, combined with the potential synergy, enables us to expand into different markets." RTR Media, Inc. will now become a wholly owned subsidiary of Encounter.com, Inc. and will focus primarily on servicing record labels by hosting online video remix contests for their featured artists, in order to increase promotional interest in the major music labels artists. Encounter.com, Inc., the publicly traded parent company, will house all of the intellectual property of the original RTR Media, Inc. and will market and license its technology to other companies as well.

About Encounter.com, Inc.

Encounter.com, Inc. provides end-to-end technology and online marketing services, including design, build, hosting, and online marketing support. We specialize in social media, video technology, and online entertainment web solutions. Encounter.com, Inc. utilizes their pre-built applications to provide the platforms in which to base solutions for businesses looking to utilize video technology to increase online collaboration and interaction. Our goal is to provide our clients with the best methods to increase user value and achieve desired business results. Simply put, Encounter.com, Inc. transforms ideas into revenues. For more information about Encounter.com, Inc., visit www.encountertech.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com
e-mail: info@StockMarketingInc.com
Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (CGLD) CGLD. (CGLD) has Short Term PowerRatings at TradingMarkets. Details on (CGLD) Short Term PowerRatings is available at This Link.

For full details on (IMUC) IMUC. (IMUC) has Short Term PowerRatings at TradingMarkets. Details on (IMUC) Short Term PowerRatings is available at This Link.

For full details on (PWRM) PWRM. (PWRM) has Short Term PowerRatings at TradingMarkets. Details on (PWRM) Short Term PowerRatings is available at This Link.

For full details on (ATNP) ATNP. (ATNP) has Short Term PowerRatings at TradingMarkets. Details on (ATNP) Short Term PowerRatings is available at This Link.

For full details on (SRGL) SRGL. (SRGL) has Short Term PowerRatings at TradingMarkets. Details on (SRGL) Short Term PowerRatings is available at This Link.

For full details on (ENCR) ENCR. (ENCR) has Short Term PowerRatings at TradingMarkets. Details on (ENCR) Short Term PowerRatings is available at This Link.